Third Quarter Conference Calls, In Brief
Executive Summary
Novartis Prexige launch delay?: Novartis anticipates launch of COX-2 inhibitor Prexige (lumiracoxib/COX-189) could be delayed until 2004. "We have here left a range for the launch. It is too early to speculate what the scientific and regulatory environment will be 15 months from now," Clinical R&D Head James Shannon says. "It is possible that we will have a straight 12-month review, and we could get approval at the end of 2003, but we feel it is conservative and gives a better indication, a better guidance, that we place the launch somewhere in 2004." Novartis plans to submit an NDA by year-end; the ongoing TARGET study will not be required for approval (1"The Pink Sheet" Nov. 12, 2001, p. 32)...
You may also be interested in...
Roche Fuzeon Dosing Convenience Is Challenge, Not Price – Physician Panel
The dosing convenience of Roche's injectable HIV drug Fuzeon could be one marketing challenge for the company, physician panelists predicted during a Banc of America-sponsored healthcare forum in New York City Dec. 11
Roche Fuzeon Dosing Convenience Is Challenge, Not Price – Physician Panel
The dosing convenience of Roche's injectable HIV drug Fuzeon could be one marketing challenge for the company, physician panelists predicted during a Banc of America-sponsored healthcare forum in New York City Dec. 11
Watson “Authorized” Generic Tri-Cyclen Will Share Market With Barr
Watson will launch an "authorized" generic version of Ortho-McNeil'soral contraceptive Ortho Tri-Cyclen when Barr enters the market with its generic under an agreement between Watson and Ortho announced Oct. 28